← Back to Search

Effect of Uterine Manipulator on Recurrence and Mortality of Endometrial Cancer

undefined
N/A
Waitlist Available
Led By Stefano Uccella
Research Sponsored by Università degli Studi dell'Insubria
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 4 years
Awards & highlights
No Placebo-Only Group

Summary

The investigators sought to retrospectively assess whether the use of a intrauterine device to manipulate the uterus does affect the long-term oncologic outcomes of patients operated by laparoscopy for endometrial cancer

See full description
Eligible Conditions
  • Endometrial Cancer

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~4 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and 4 years for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Disease recurrence
Secondary study objectives
disease specific survival
overall survival

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Group I: NO MANIPULATORExperimental Treatment0 Interventions
Patients who were operated for endometrial cancer by laparoscopy without the use of a uterine manipulator
Group II: MANIPULATORExperimental Treatment1 Intervention
Patients who were operated for endometrial cancer by laparoscopy with the use of a uterine manipulator
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
UTERINE MANIPULATOR
2016
N/A
~960

Who is running the clinical trial?

Università degli Studi dell'InsubriaLead Sponsor
82 Previous Clinical Trials
19,649 Total Patients Enrolled
3 Trials studying Endometrial Cancer
1,639 Patients Enrolled for Endometrial Cancer
Stefano UccellaPrincipal InvestigatorUniversità degli Studi dell'Insubria
1 Previous Clinical Trials
36 Total Patients Enrolled
~102 spots leftby Feb 2026